INTRODUCTION
The HIV pediatric epidemic continues to expand, 1 with an estimated 3.4 million children under 15 years of age living with HIV as of December 2010. However, although great strides have been made to expand access to care for adults, access and use of pediatric antiretroviral therapy (ART) have lagged behind. 1 Providing ART to children poses unique challenges to HIV care programs. This may be due to weak linkage between prevention of mother-to-child transmission (PMTCT) and child health services, poor access to HIV diagnostic tests in children, and complexities of infant and child HIV care differing from those generally encountered among adults. Limited access to pediatric antiretroviral drugs and availability of drugs in appropriate formulations and the reliance on an individual other than the patients themselves to provide the medications are only a few of the challenges. 2, 3 Thus, overall, at the end of 2010, only 23% of the estimated 2,020,000 HIVinfected children ,15 years of age eligible for ART were treated in low-and middle-income countries, with coverage rates varying from 2% in Sudan to 88% in Botswana. 1, 4 Characteristics at ART initiation and short-term outcomes (mortality, retention in program) are evolving in pediatric ART programs. Recent reports show decreased mortality in children after ART initiation, [5] [6] [7] [8] [9] [10] [11] [12] but children continue to initiate ART with advanced disease. 13, 14 In addition, programs that have rapidly scaled up ART have, as in adults, high loss to follow-up (LTFU) rates. 6 In adults, high rates of LTFU correspond to underreported mortality 15, 16 suggesting that in children a significant proportion of child mortality may be unseen as well. Several site-specific and individual patient factors could explain the heterogeneity in effectiveness of HIV-care program outcomes. 17 However, factors associated with mortality and cohort attrition in children have received little attention to date and need further investigation to evaluate the impact of ART scale-up on pediatric outcomes at the program level. 17 In 2006, the US National Institutes of Health launched the International epidemiologic Databases to Evaluate AIDS (IeDEA) initiative to better describe trends in HIV epidemiology in the context of ART access by region of the world (http:// www.iedea-hiv.org). As part of the pediatric component of the IeDEA multiregional collaboration, we have combined data across 4 resource-constrained IeDEA regions to study 18-month mortality and loss to follow-up rates after ART initiation and explore their baseline individual and site-specific determinants.
METHODS Ethics Statement
Each participating pediatric HIV clinic formally agreed to be included in the IeDEA collaboration, with local Institutional Review Board and NIH approval.
Study Design
We conducted a multiregional cohort analysis within the IeDEA collaboration. All clinical centers from 4 (Asia Pacific, East Africa, Southern Africa, and West Africa) of the 6 IeDEA Collaboration regions collecting data on pediatric HIV care were eligible.
Study Population
All HIV-infected children (positive polymerase chain reaction ,18 months or positive serology $18 months) aged ,16 years at ART initiation, with documented gender, who were ART naive (except for exposure to perinatal PMTCT prophylaxis) and who initiated $3 antiretroviral drugs from November 21, 1995 (first ART initiation in Asia Pacific), to June 24, 2009 , were included irrespective of the first-line ART regimen. The database was closed on December 20, 2009. Each ART program within the consortium has its own protocol for clinical follow-up and laboratory testing. However, HIV-infected children were typically seen in clinics at least every 3 months, and their CD4 count was measured every 6 months to monitor their immunological response to ART. Routine viral load monitoring was not available at most sites.
Outcomes
The outcomes of interest were (1) mortality, defined as a death documented in the database; (2) loss to follow-up, defined as failure to return to the clinic for .6 months after the last clinic visit was reported in the database, the closing date of the database was .6 months since that visit, and the child was not known to be dead or have transferred to another treatment site.
Key Variables and Definitions
Baseline was defined as the date of ART initiation. Age at ART initiation was categorized into 5 groups: ,12 months, 1-2 years, 3-4, 5-9, and $10 years. The severity of immunodeficiency was defined according to the 2006 WHO criteria 18 : CD4% , 25% or CD4 count ,1500 cells per cubic millimeter for children ,12 months; CD4% , 20% or CD4 count , 750 cells per cubic millimeter for children between 12 and 35 months; CD4% , 15% or CD4 count , 350 cells per cubic millimeter for children between 36 and 59 months; CD4% , 10% or CD4 count ,200 cells per cubic millimeter for children $5 years. According to the toxicity scales from the National Institute of Allergy and Infectious Diseases, severe anemia was defined as hemoglobin (Hb) ,7 g/dL for children $57 days old. Baseline values for laboratory and clinical measurements were defined as the values closest to ART initiation that fell into a window of 90 days before ART initiation and 30 days after. Site-specific variables from a pediatric site survey conducted in 2009 were also analyzed 19 : IeDEA region, rural versus urban site, length of clinic experience with provision of pediatric ART, clinic size (total number of children included per site during the study period), family-centered care approach, use of generic drug combinations, free access to ARV drugs, free access to opportunistic infection (OI) prophylaxis, free access to laboratory tests, documentation of death events, and lost-tofollow-up tracking system. receiving and combining data from individual sites, verifying data quality, harmonizing lists and definitions of variables. In addition, each regional data center develops and implements methods for analyzing cohort data and performs training on data collection, processing, and cleaning. Four regional data sets were prepared and were transmitted to us by the regional data centers. These data were merged for the purpose of this analysis.
Statistical Methods
Baseline categorical data are presented as frequencies (percentage) and continuous data as medians and interquartile ranges (IQRs). Continuous variables were compared using the Kruskal-Wallis test and categorical variables using x 2 or Fisher exact tests. Heterogeneity of baseline differences between regions was tested. A competing risk model was used to analyze the independent risk of the 2 failures types: death and LTFU. LTFU is a competing cause of death, potentially increasing the risk of death because of ART interruption. Thus, assumptions about the independence of these 2 outcomes are not realistic. For this reason, we used a cumulative incidence function to estimate the cumulative probability of each outcome over 18 months of follow-up. 20 Cumulative incidence functions were also estimated adjusted for baseline covariates.
To study correlates of the 2 outcomes, univariate analyses were first conducted. Second, we conducted multivariate competing risk analysis, using the fine and gray proportional subdistribution hazard regression model using the R statistical software version 2.11.1 (The R foundation for Statistical computing, Vienna, Austria) with the cmprsk package. 21, 22 Two multivariate models were created using this methodology. Variables were included in the full model if they were associated with each outcome in univariate competing risk analysis with P , 0.25. 23 A final model was then created, by using a backward elimination procedure with a P value ,0.05 considered statistically significant in the adjusted analysis. There was a substantial modification of the effect of the "search LTFU variable" in the full model. However, as subgroup analyses could not be run with too small sample sizes in some of the strata, we omitted the variable "search LTFU" from both mortality and LTFU models. The adjusted subdistribution hazard ratios (asHR) were reported with their 95% confidence intervals (95%CIs). Variables for which data were available on ,70% of the patients were not included. Table 1) .
RESULTS

Description of Sites
The sites were predominantly urban or semirural public sector clinics (Table 1 ). Significant between-region heterogeneity in site characteristics was observed. Asian and EastAfrican cohort sites primarily had ,250 children registered, whereas Southern and West-African cohort sites primarily had .500 active patients (P , 0.01). Across these 4 regions, 93.8% of sites had free access to all laboratory tests, and 93.3% had free access to first-line ART. Rates of access to free OI prophylaxis were lower overall (83.3%) with substantial regional heterogeneity: 77.2% in Asia, 100.0% in East Africa, 96.1% in Southern Africa, and only 41.0% in West Africa (P , 0.001). Free access to second-line therapy was available for 87.8% of sites overall but in significantly fewer sites in West Africa, 57.5% (P , 0.001). Most sites (65.1%) traced children who were lost to follow-up using home visit and telephone calls with, again, substantial regional heterogeneity observed: 81.4% of Asian, 91.5% of East-African, 64.4% of Southern-African, and only 29.9% of West-African sites (P , 0.001, Table 1 ).
Characteristics of Individual Patients and Antiretroviral Regimens at ART Initiation
At ART initiation, the median age was 5 years (IQR: 2-9); median CD4 percentage was 12% (IQR: 7-18) with 51.8% of children being immunodeficient, and 19.9% having clinical AIDS. NNRTI-based regimens were the most common first-line antiretroviral drug regimens (76.9%), followed by those with a PI (20.1%), with other combinations accounting for the remaining 3%. These baseline patient characteristics differed significantly between regions (Table 1 ). Median CD4 percentage and age were 7% and 7 years, respectively, in Asia; 12% and 6 years in East Africa; 14% and 4 years in Southern Africa; and 13% and 5 years in West Africa (P , 0.001). More than 90% of the children in Asia and East Africa started ART with an NNRTI and 2 NRTIs, compared with 66.4% of children in Southern Africa and 69.3% in West Africa. The proportions of children initiating ART before 2005 were 40.0% in Asia, 6.4% in East Africa, 21.6% in Southern Africa, and 31.6% in West Africa (P , 0.001).
Mortality and Loss to Follow-Up Rates Across Regions
Among 13,611 children followed up for a median length of 18 months (IQR: 7-32) and contributing 20,417 person-years of follow-up by 18 months after ART initiation, 5.7% of children had died, 12.3% were lost to follow-up, and 8.6% had been transferred out of the clinic (Table 2) . Mortality varied from 4.3% in East Africa to 7.4% in West Africa, whereas LTFU varied even more widely from 4.1% in Asia to 21.8% in West Africa (P , 0.001). Transfer-out rates varied from 0.4% of children in East Africa to 16.4% in Southern Africa (Table 2) .
Overall, using a competing risk model with death and LTFU as competing events, the cumulative incidence rates of death were 4.5% (95% CI: 4.2 to 4.8), 5.5% (95% CI: 5.1 to 5.9), and 6.3% (95% CI: 5.9 to 6.7) at 6, 12, and 18 months, respectively. The estimated crude cumulative incidence of death at 18 months was the highest in West Africa (7.9%, 95% CI: 6.9 to 8.9), followed by Southern Africa (6.2%, 95% CI: 5.6 to 6.8), Asia (5.7%, 95% CI: 4.7 to 7.0), and East Africa (4.9%, 95% CI: 4.2 to 5.8; P , 0.01). When adjusting for age, WHO clinical stage and CD4 at ART initiation, along at ART initiation along with type of ART regimen, year of ART initiation, type of facility, free access to laboratory tests, and to ARV, nonurban site, and cohort size, the risk of loss to followup was 21.8% in West Africa, 14.0% in East Africa, 9.0% in Southern Africa, and 4.1% in Asia (P , 0.01, Table 3 ).
Factors Associated With the Risk of Dying
The crude estimated 18-month cumulative mortality was significantly higher in children ,24 months old at baseline, compared with that in older children (P , 0.01, Fig. 1 ). It was also significantly higher (10.5%) in children with severe immunodeficiency (CD4 , 10%) at baseline, compared with that in the other groups: 4.7% in those with CD4 (10%-20%), 4.5% in those with CD4 $20%, and 5.4% in those with unknown CD4 percentage (P , 0.01, Fig. 2 ). We observed a significantly higher mortality in clinics with no LTFU search compared with those with any search in univariate analysis (see Table, Supplemental Digital Content 1, http://links.lww.com/QAI/A371).
The adjusted statistical analysis using a competing risk model (Table 3; see Table, Supplemental Digital Content 1, http://links.lww.com/QAI/A371) identified the following individual baseline correlates of higher 18-month risk of dying (asHRs and their 95% CIs) age ,12 months (asHR 2.8; CI: 2.2 to 3.5; P , 0.01) and age 1-2 years (asHR 1.5; CI: 1.2 to 2.0, P , 0.01) compared with 10-15 years (the reference group); clinical AIDS or stage-4 disease versus earlier stages (asHR 2.1; CI:1.8 to 2.5, P , 0.01); CD4% , 10% versus $20% (asHR 3.0; CI: 2.3 to 3.9, P , 0.01); or missing CD4% (asHR 1.5; CI: 1.2 to 2.0, P , 0.01). Sitespecific variables associated with higher mortality were the following: attending a private facility (asHR 1.5; CI: 1.1 to 2.0, P , 0.01) or an unknown type of facility (asHR 2.4; CI: 1.6 to 3.8, P , 0.01) compared with a public sector 1, being followed up in a large size cohort (500-800 children; asHR 1.8; CI: 1.4 to 2.3, P , 0.01) compared with ,250 children; receiving care in West Africa, the site of highest mortality (asHR 1.3; CI: 1.0 to 1.7, P = 0.04) compared with East Africa, the region with the lowest mortality rates. Mortality in Southern Africa and Asia did not differ from that in East Africa. No other pairwise regional comparison was statistically significant when adjusting for all other patient-level and site-specific predictors.
Factors Associated With Loss to Follow-Up
The crude estimated 18-month cumulative incidence of LTFU was significantly higher in children ,24 months at baseline compared with that in older children (P , 0.01, Fig. 1 ) and in children with CD4 percentage $20% or unknown percentage at baseline, compared with those with CD4 percentage ,20% (P , 0.01, Fig. 2 ). In the adjusted statistical analysis, a number of patient-level and site-specific factors were identified as independent predictors of higher LTFU hazards adjusted for the competing risk of death (Table 3; see Table, initiated therapy before 2005, receiving care in a nonurban clinic (asHR 1.7; CI: 1.4 to 1.9, P , 0.01) versus being treated at an urban clinic; having to pay for laboratory tests (asHR 2.6, 95% CI: 1.9 to 3.5, P , 0.01) versus receiving free access to laboratory tests and having to pay for first-line antiretrovirals (asHR 5.0, 95% CI: 3.4 to 7.3, P , 0.01) versus having access to free ART, being a member of a larger cohort (ie, 1 with 500-800 children; asHR 1.8, 95% CI: Table 5 , Supplemental Digital Content 1, http://links.lww.com/QAI/A371). Predictors of a less frequent LTFU were as follows: having CD4% (10%-20%, asHR 0.8; CI: 0.7 to 1.0, P = 0.03) versus $20%, receiving care in a private clinic (asHR 0.2 CI: 0.1 to 0.3, P , 0.01) rather than in a public clinic, and cohort size (250-500, asHR 0.8 CI: 0.6 to 0.9, P , 0.01).
DISCUSSION
As HIV treatment is rapidly scaled up toward universal access in the first decade of the 21st century, the IeDEA multiregional pediatric collaboration provides a unique opportunity to monitor, analyze, and compare children's outcomes taking into account patient and program-level factors while accounting for regional heterogeneity in these factors, in large-scale care and treatment programs in low-and middle-income countries. This analysis included 13,611 children contributing with 20,417 child-years of follow-up in a large number of pediatric cohorts. The overall cumulative mortality was measured at 5.7%, whereas LTFU rate was 12.3% after 18 months on ART, with marked differences of these estimates between the 4 regions studied: Asia, East Africa, West Africa, and Southern Africa.
There are important observations gleaned from our study. First, the 18-month mortality in children on ART is much lower than the reported mortality estimates among untreated children before the ART era, 24, 25 arguing for a clear benefit of ART as a pediatric HIV intervention. Our mortality estimates are consistent with those of previous reports of studies conducted among HIV-infected children on ART in resource-constrained countries with reported mortality rates, ranging from 6.3% to 11.5%, usually obtained in small-size cohorts and in the early periods of the ART scale-up. 5, 7, [9] [10] [11] [12] [13] [14] 26 Despite heterogeneity between regions, our findings consistently reflect the impact of overall delayed ART initiation in children when adjusting for individual, programmatic, and regional factors. Indeed, independent individual predictors of residual mortality on ART (advanced clinical stage of HIV disease, and severe immunosuppression) reflect late access to ART. In addition, most (71%) deaths in this data set occurred within the first 6 months after ART initiation, advocating for earlier and increased access to ART initiation in the pediatric population. These findings are consistent with those reported in previous studies 5, 7, [9] [10] [11] [12] [13] [14] and in individual IeDEA regions. 8, [26] [27] [28] A number of site-specific variables also explained part of the observed mortality: A greater cohort size increased mortality risk, possibly reflecting the impact of skilled health care staff shortages or work overload, receiving care in Western Africa independently increased the mortality by 40% compared with in East Africa. Although delayed ART initiation is common in all regions, there were significant differences in site-level factors such as having lower access to free HIV services in Western Africa compared with other regions (laboratory tests, OI prophylaxis, first-line, and second-line ART).
Second, the 18-month LTFU rates were unacceptably high and differed substantially across regions, with significant 3.5-fold and 3.1-fold increased hazards in East Africa and West Africa compared with the risk in Asia. Multiple sources of between-region heterogeneity could explain these higher LTFU rates including variations in (1) operational definitions of LTFU and patient tracing systems, (2) lack of access to free HIV services (laboratory tests, antiretroviral drugs, and OI prophylaxis) in West Africa compared with other regions, (3) failure to accurately capture patient transfers as documented transfer-out rates differed significantly between regions, as very few transfers (,1%) were recorded in East and West Africa compared with 16% in Southern Africa, (4) levels of decentralization of HIV pediatric care out of urban hospitals, and (5) reliability of drug supply chain management for non-NNRTI-based regimens, which are less affordable and accessible in East and West Africa compared with that in Southern Africa. Requiring the patients' families to shoulder the fees for HIV care and clinical services was associated with higher LTFU rates as has previously been reported in adults. 29 In addition to patient-level and site-specific factors, our analysis illustrated the substantial impact of the large-scale ART rollout in lower-income countries over the past decade. Initiation of ART after 2005 and site cohorts with (500-800) children were associated with increased hazard of LTFU, whereas cohorts with ,500 children had lower LTFU rates. As antiretroviral treatment decreases mortality, we hypothesize that the number of HIV-infected children treated will continue to increase over time, particularly in regions where transfer-out rates are low, such as in East Africa and West Africa. This substantial increase in the number of HIV-infected children followed in individual health facilities and the associated increased workload may further negatively impact the standard of care. Finally, the political instability and violence crisis could have also increased the rates of LTFU in East and West Africa, as this was recently investigated in Kenya. 30 We observed the seemingly contradictory finding that treatment at private clinics (where presumably care is not free) were associated with higher rates of death but lower rates of LTFU compared with being cared at public clinics (more frequently free of charge). Although not explicitly measurable with these data, we suspect that this dichotomy may reflect that record-keeping practices may be better in private settings with a significantly higher mortality rates documented and lower LTFU rates compared with public settings, with a substantial proportion of excess LTFU being unreported mortality.
Limitations must be acknowledged in our study. The mortality rate we observed at 18 months is likely to be underestimated because of the high rates of LTFU, with a proportion of those lost more likely to die soon after defaulting from the program. Indeed, mortality has been commonly underreported in African adult ART programs due to limited access to care and the frequent occurrence of death at home. 16 The same finding was recently observed in children in East Africa where mortality and disclosure issues, including fear of family or community discrimination, were the most important reasons why children became lost to follow-up. 31 Thus, it would be valuable to further ascertain outcomes at least in a sample of those children lost to follow-up in pediatric programs to correct the mortality rates as proposed in adults. 32 Even though this information was available in a small number of cohorts in this study, this was not attempted here so our estimates are likely underestimating overall mortality rates, particularly in regions with high rates of LTFU. This means that pediatric outcomes may be much worse than reported, particularly in regions, such as East and West Africa, with both high mortality and LTFU rates.
When the cohort size is large, as in this case, statistical significance testing of baseline variables may produce highly significant statistical differences, even when they may have little clinical or programmatic implication. For example differences in gender between the regions was ,5% (absolute) but was still highly statistically significant. Data quality is another concern when analyzing such large collaborative data sets is. Lack of data completeness and substantial interstudy heterogeneity may reduce the accuracy of our results compared with studies coming from more homogeneous settings. Also, data on factors related to ART adherence or other social issues such as disclosure and orphan status, which were not generally available in our data, would help to better explain clinical outcomes in HIV-infected children. Smaller studies where these issues were documented have reported that disclosure is associated with ART adherence and needs to be monitored in programs. 33 In addition, substantial rates of missing data on a number of target outcomes and their predictors and record-keeping practices have been varied over time and between regions. In the adjusted regression analyses, when missing variables were included as a separate category within variables, this may introduce bias in the effect estimates, 34 and this was the reason why we did not included variables if missing data were .70%.
Finally, our study may not be representative of all children on ART in these regions as most of the data were gathered from urban sites, in which the standard of care may be higher than in rural areas. Thus, we hypothesize that the programmatic deficiencies identified here could be worse in less structured clinical settings or at lower levels of the health care system. Nevertheless, we are confident of our main findings, which raise significant operational concerns regarding the impact of both delayed ART start as measured by the high rates of advanced disease at the time of care initiation in our cohort, and the importance of long-term retention to care once enrolled into a program.
Despite the possibly superior level of care in our facilities, and concerns with missing data or quality of data collection, our mortality outcomes confirm that there is still a gap in achieving the standard of implementation of early ART in all HIV-infected children ,2 years old as recommended in the 2010 WHO guidelines. 35 Increasing early access to ART would decrease early on-ART mortality as demonstrated in the CHER trial. 36 This is one of the primary operational challenges in pediatric care in these settings, pointing to the need for earlier identification of HIV-infected children, as soon as possible after birth, followed by expedited linkages from testing to ART initiation.
Retention in HIV care is one of the most important challenges faced by health care workers and HIV-implementing partners as the coverage of HIV care and ART have improved for children in low-income countries. 37 In this study, high LTFU rates were associated with rapid scale-up, suggesting problems of adaptation of the health care organization and/or staff shortages. Evolving to smaller decentralized clinics rather than to expanding large single programs and task shifting could result in increased access to ART services and good program outcomes as recently reported in Malawi. 38, 39 Finally, LTFU was strongly associated with fees for ART services. This predictable finding, already reported in adults 29 underscores the urgent need for universal free access to all ART services for children too.
Future research should assess whether health systems are meeting the challenges of providing care linkages between all points on the HIV care continuum from early infant diagnosis, to ART initiation and long-term retention of patients. It is also crucial to better document the causes of loss to program and to propose sustainable approaches to increase retention in HIV pediatric programs in lower-income countries.
With this aim, access to treatment through a familycentered approach should be considered. In this model, primary caregivers on treatment can be sources of continuity, knowledge, and strength for pediatric patients and other HIVinfected family members. 40, 41 Although data quality of such international data sets should be improved and documentation of clinical outcomes could have been more complete, this multiregional collaborative study offered a unique opportunity to improve our understanding of the rapidly expanding pediatric ART services taking into account both patient-level and sitespecific factors. Such analyses should be repeated to explore secular trends in the second decade of wide ART use in these settings. Large-scale ART for children in resource-limited settings is feasible, but innovative and sustainable approaches are urgently required to improve early ART initiation, and retain children in ART programs in lower-income countries.
